Checkpoint Therapeutics Inc. (NASDAQ: CKPT) is 20.00% higher on its value in year-to-date trading and has touched a low of $1.05 and a high of $4.50 in the current 52-week trading range. The CKPT stock was last observed hovering at around $2.71 in the last trading session, with the day’s gains setting it 0.47% off its average median price target of $17.00 for the next 12 months. It is also 84.1% off the consensus price target high of $20.00 offered by 3 analysts, but current levels are 60.25% higher than the price target low of $8.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $3.18, the stock is 19.28% and 25.87% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.13 million and changing 17.34% at the moment leaves the stock 41.00% off its SMA200. CKPT registered 97.52% gain for a year compared to 6-month gain of 89.29%. The firm has a 50-day simple moving average (SMA 50) of $2.5908 and a 200-day simple moving average (SMA200) of $2.4647.
The stock witnessed a 27.20% loss in the last 1 month and extending the period to 3 months gives it a 12.77%, and is 22.31% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.52% over the week and 7.90% over the month.
Checkpoint Therapeutics Inc. (CKPT) has around 8 employees, a market worth around $213.54M and $1.10M in sales. Distance from 52-week low is 202.86% and -29.33% from its 52-week high. The company has generated returns on investments over the last 12 months (-132.20%).
Checkpoint Therapeutics Inc. (CKPT) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Checkpoint Therapeutics Inc. (CKPT) is a “Buy”. 3 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Checkpoint Therapeutics Inc. is expected to release its quarterly report on 05/13/2021 and quarterly earnings per share for the current quarter are estimated at -$0.09 with sales reaching $300k over the same period.The EPS is expected to grow by 45.00% this year, but quarterly earnings will post -17.40% year-over-year. Quarterly sales are estimated to grow 1,100.00% in year-over-year returns.
Checkpoint Therapeutics Inc. (CKPT) Top Institutional Holders
79 institutions hold shares in Checkpoint Therapeutics Inc. (CKPT), with 8.57M shares held by insiders accounting for 12.62% while institutional investors hold 24.48% of the company’s shares. The shares outstanding are 56.41M, and float is at 53.20M with Short Float at 3.98%. Institutions hold 21.39% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 3.07 million shares valued at $8.23 million. The investor’s holdings represent 10.64% of the CKPT Shares outstanding. As of Sep 29, 2020, the second largest holder is CVI Holdings, LLC with 2.62 million shares valued at $7.03 million to account for 9.09% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 2.3 million shares representing 7.96% and valued at over $6.15 million, while Sabby Management, LLC holds 3.23% of the shares totaling 0.93 million with a market value of $2.5 million.
Checkpoint Therapeutics Inc. (CKPT) Insider Activity
A total of 1 insider transactions have happened at Checkpoint Therapeutics Inc. (CKPT) in the last six months, with sales accounting for 1 and purchases happening 0 times. The most recent transaction is an insider sale by GRAY WILLIAM GARRETT, the company’s Chief Financial Officer. SEC filings show that GRAY WILLIAM GARRETT sold 2,406 shares of the company’s common stock on Dec 22 at a price of $2.79 per share for a total of $6712.0. Following the sale, the insider now owns 0.36 million shares.
Checkpoint Therapeutics Inc. (CKPT): Who are the competitors?
Omeros Corporation (OMER) is 22.54% up on the 1-year trading charts. Short interest in the company’s stock has fallen -4.25% from the last report on Nov 12, 2020 to stand at a total of 2.21 million short shares sold with a short interest ratio of 4.51.